514.00SEK+3.42%Mkt Cap: 30.32B SEKP/E: 44.85Last update: 2026-05-13
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphi…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)44.85
P/E (Forward)33.11
PEG—
P/B6.85
P/S13.53
EV/EBITDA32.48
EV/Revenue11.84
EPS (TTM)11.36
EPS (Forward)15.39
Cash Flow & Leverage
FCF Yield1.69%
FCF Margin22.90%
Operating CF869.30M SEK
CapEx (TTM)138.52M SEK
Net Debt/EBITDA-4.61
Net Debt-3.77B SEK
Technical
SMA 50505.84 (+1.6%)
SMA 200605.85 (-15.2%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)95.19K
Avg Vol (10d)186.76K
Technical Indicators
RSI (14)45.0
MACD4.3139
MACD Signal9.7615
MACD Hist.-5.4476
BB Upper587.38 SEK
BB Middle546.50 SEK
BB Lower505.62 SEK
BB Width14.96%
ATR (14)22.37 SEK
Vol Ratio (20d)1.12x
52W Range
430.8026% of range754.50
52W High754.50 SEK
52W Low430.80 SEK
Profitability
Gross Margin93.11%
EBITDA Margin36.44%
Profit Margin32.47%
Oper. Margin31.59%
ROE17.37%
ROA15.52%
Revenue Growth-4.50%
Earnings Growth-27.10%
Balance Sheet
Debt/Equity0.03
Current Ratio11.57
Quick Ratio10.88
Book Value/Sh74.41 SEK
Cash/Share65.21 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.59.51M
Float36.60M
Insiders36.28%
Institutions37.79%
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)770.13 SEK
Target Range620.00 SEK – 914.00 SEK
# Analysts8
Company
Market Cap30.32B SEK
Enterprise Value26.51B SEK
Revenue (TTM)2.24B SEK
Gross Profit2.11B SEK
Net Income (TTM)735.57M SEK
Revenue/Share37.70 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees263
Last Price514.00 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—